Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

33.23 +0.30 (+0.91%)

Streaming Delayed Price Updated: 3:23 PM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

NASDAQ:GMAB, a strong growth stock, setting up for a breakout. ↗

February 08, 2024

Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗

February 08, 2024

While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.

Via Chartmill

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

February 02, 2024

From Genmab A/S

Via Business Wire

Cracking The Code: Understanding Analyst Reviews For Genmab ↗

January 29, 2024

Via Benzinga

What's Going On With Danish Healthcare Firm Genmab Stock? ↗

January 23, 2024

Genmab's legal update on Darzalex: Arbitrator dismisses bid for milestone payments. Despite this, diverse revenue sources, including royalty agreements, contribute to strong growth.

Via Benzinga

Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB. ↗

January 18, 2024

NASDAQ:GMAB is showing good growth, while it is not too expensive.

Via Chartmill

9 Analysts Have This to Say About Genmab ↗

November 28, 2023

Via Benzinga

NASDAQ:GMAB is not too expensive for the growth it is showing. ↗

November 10, 2023

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.

Via Chartmill

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer

January 09, 2024

From Genmab A/S

Via Business Wire

TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

January 09, 2024

From Pfizer Inc.

Via Business Wire

Analyst Expectations for Genmab's Future ↗

November 08, 2023

Via Benzinga

NASDAQ:GMAB, a strong growth stock, setting up for a breakout. ↗

November 01, 2023

GENMAB A/S -SP ADR (NASDAQ:GMAB)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

What 13 Analyst Ratings Have To Say About Genmab ↗

October 13, 2023

Via Benzinga

Expert Ratings for Genmab ↗

September 26, 2023

Via Benzinga

NASDAQ:GMAB stands out as a growth opportunity that won't break the bank. ↗

December 26, 2023

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.

Via Chartmill

Oracle Reports Weak Sales, Joins Kinetik, Lucid Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

December 12, 2023

U.S. stock futures were higher this morning, with the Dow Jones futures gaining over 50 points on Tuesday.

Via Benzinga

Topics Stocks

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

December 09, 2023

From Genmab A/S

Via Business Wire

In the world of growth stocks, NASDAQ:GMAB shines as a value proposition. ↗

December 05, 2023

Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB).

Via Chartmill

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

November 27, 2023

From Genmab A/S

Via Business Wire

7 Must-Buy Stocks That Are on Ridiculous Discount Now ↗

November 13, 2023

With Wall Street still chasing after the usual suspects in the tech ecosystem, astute investors may wish to target stocks on sale.

Via InvestorPlace

7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗

November 09, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

Via InvestorPlace

Topics Economy

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

November 02, 2023

From Genmab A/S

Via Business Wire

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

October 22, 2023

From Seagen Inc.

Via Business Wire

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗

October 20, 2023

While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable.

Via Chartmill

United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 18, 2023

U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher ↗

September 26, 2023

With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio.

Via InvestorPlace

Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

September 25, 2023

From Genmab A/S

Via Business Wire

EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

September 25, 2023

From Genmab A/S

Via Business Wire

Why Shares of Iovance Biotherapeutics Dropped Thursday ↗

September 14, 2023

The biotech stock's lead therapy is looking at some competition.

Via The Motley Fool

AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst ↗

September 11, 2023

On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.